Kazuhiko Nakagawa
YOU?
Author Swipe
View article: Retraction Note: Identification of thymidylate synthase as a potential therapeutic target for lung cancer
Retraction Note: Identification of thymidylate synthase as a potential therapeutic target for lung cancer Open
View article: Durvalumab plus irinotecan + cisplatin for untreated extensive-stage small cell lung cancer: REBORN, phase II study (WJOG13520L)
Durvalumab plus irinotecan + cisplatin for untreated extensive-stage small cell lung cancer: REBORN, phase II study (WJOG13520L) Open
The REBORN study did not demonstrate the expected efficacy of IP plus durvalumab in untreated ES-SCLC, with its efficacy and safety generally comparable to those of EP plus durvalumab.
View article: Safety and effectiveness of tepotinib in patients with unresectable, advanced or recurrent non-small cell lung cancer with <i>METex14</i> skipping alterations: post-marketing surveillance in Japan
Safety and effectiveness of tepotinib in patients with unresectable, advanced or recurrent non-small cell lung cancer with <i>METex14</i> skipping alterations: post-marketing surveillance in Japan Open
Objective Tepotinib has shown clinical benefits in patients with non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping alterations. The objective of this post-marketing surveillance (PMS) was to assess the safety and …
View article: Exploration of genes related to the development of cancer of unknown primary
Exploration of genes related to the development of cancer of unknown primary Open
The biological basis of the development of cancer of unknown primary (CUP) remains largely unknown, with no evidence of whether a common biological basis exists at present. Our previous multicenter clinical study predicted the primary site…
View article: Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC
Serum VEGF-A as a biomarker for the addition of bevacizumab to chemo-immunotherapy in metastatic NSCLC Open
Anti-vascular endothelial growth factor (VEGF) agents in combination with immunotherapies have improved outcomes for cancer patients, but predictive biomarkers have not been elucidated. We report here a preplanned analysis in the previousl…
View article: Intensity-Modulated Radiotherapy for Locally Advanced Lung Cancer in the Immunotherapy Era: A Prospective Study WJOG12019L
Intensity-Modulated Radiotherapy for Locally Advanced Lung Cancer in the Immunotherapy Era: A Prospective Study WJOG12019L Open
University Hospital Medical Information Network database ID: UMIN000038366.
View article: Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset
Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated EGFR-Mutated Metastatic NSCLC: RELAY Japanese Subset Open
NCT02411448.
View article: First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial
First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial Open
Nivolumab, in addition to carboplatin, paclitaxel, and bevacizumab, remained to demonstrate significantly longer PFS and long-term OS benefit compared with placebo in the first-line treatment of patients with nonsquamous NSCLC. The extende…
View article: Laparoscopic Distal Pancreatectomy for Lymph Node Metastasis around Splenic Artery from Hepatocellular Carcinoma in a Patient with Portal Annular Pancreas
Laparoscopic Distal Pancreatectomy for Lymph Node Metastasis around Splenic Artery from Hepatocellular Carcinoma in a Patient with Portal Annular Pancreas Open
LDP was successfully performed for lymph node metastasis around the splenic artery in an HCC patient and resulted in long-term survival. Surgeons should be aware of the unique anatomical characteristics of PAP during LDP.
View article: Radiotherapy-Free Pembrolizumab Combined with Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer with Pd-L1 TPS ≥50%: A Phase II Study (Evolution Trial: WJOG11819L)
Radiotherapy-Free Pembrolizumab Combined with Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer with Pd-L1 TPS ≥50%: A Phase II Study (Evolution Trial: WJOG11819L) Open
View article: Evaluation of immune checkpoint inhibitor efficacy for solid tumors with <i>CD274</i> (PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwide database
Evaluation of immune checkpoint inhibitor efficacy for solid tumors with <i>CD274</i> (PD-L1 gene) amplification identified by comprehensive genomic profiling: retrospective study based on a nationwide database Open
Background Amplification of the programmed cell death-ligand 1 gene ( CD274 ) is highly prevalent and associated with a high response rate to immune checkpoint inhibitors (ICIs) in lymphomas, and is also a potential biomarker for ICI treat…
View article: Dual single‑nucleotide polymorphism biomarker combination for opioid selection to treat cancer pain
Dual single‑nucleotide polymorphism biomarker combination for opioid selection to treat cancer pain Open
We have been exploring biomarkers that could help physicians select the appropriate opioid for individualized treatment of cancer pain. Recently, we identified a single nucleotide polymorphism (SNP) of CCL11 (rs17809012) as one such…
View article: Patient‐Initiated Nationwide Survey on Testing for Actionable Oncogenic Drivers in Non‐Small Cell Lung Cancer in Japan
Patient‐Initiated Nationwide Survey on Testing for Actionable Oncogenic Drivers in Non‐Small Cell Lung Cancer in Japan Open
Background Previous reports indicated still low implementation rates of multigene testing for advanced non‐small cell lung cancer (NSCLC) in Japan. Methods This is a retrospective study launched at the initiative of lung cancer patients. P…
View article: Efficacy in patients with <i>EGFR</i> -positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: <i>post hoc</i> analyses from ARCHER 1050
Efficacy in patients with <i>EGFR</i> -positive non-small-cell lung cancer treated with dacomitinib who had skin adverse events: <i>post hoc</i> analyses from ARCHER 1050 Open
Aim: We investigated association between skin adverse events (AEs) and efficacy with dacomitinib in patients with EGFR-positive non-small-cell lung cancer (NSCLC).Methods: Post hoc analyses from ARCHER 1050 eval…
View article: Corrigendum to “A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation–positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platinum-based chemotherapy” [Lung Cancer 177 (2023) 44–50]
Corrigendum to “A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation–positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKI and platinum-based chemotherapy” [Lung Cancer 177 (2023) 44–50] Open
View article: Acute exacerbation predicting poor outcomes in idiopathic interstitial pneumonia and advanced lung cancer patients undergoing cytotoxic chemotherapy
Acute exacerbation predicting poor outcomes in idiopathic interstitial pneumonia and advanced lung cancer patients undergoing cytotoxic chemotherapy Open
View article: Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade
Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade Open
BACKGROUNDPrecise stratification of patients with non-small cell lung cancer (NSCLC) is needed for appropriate application of PD-1/PD-L1 blockade therapy.METHODSWe measured soluble forms of the immune-checkpoint molecules PD-L1, PD-1, and …
View article: Long‐term follow‐up results from <scp>KEYNOTE</scp>‐041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanoma
Long‐term follow‐up results from <span>KEYNOTE</span>‐041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanoma Open
Pembrolizumab demonstrated an acceptable safety profile and promising antitumor activity in Japanese patients with advanced melanoma in the phase 1b KEYNOTE‐041 (Study of Pembrolizumab [MK‐3475] in Participants With Advanced Melanoma) tria…
View article: Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer
Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer Open
View article: Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCM
Association between skin toxicity and efficacy of necitumumab in squamous non-small-cell lung cancer: a pooled analysis of two randomized clinical trials-SQUIRE and JFCM Open
A significant association was found between necitumumab-induced skin toxicity and efficacy. These results are consistent with the previously reported association between other EGFR inhibitors-induced skin toxicity and efficacy.
View article: The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma
The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma Open
View article: Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722 Open
PURPOSE The phase III CheckMate 722 trial (ClinicalTrials.gov identifier: NCT02864251 ) evaluated nivolumab plus chemotherapy versus chemotherapy in patients with epidermal growth factor receptor ( EGFR)–mutated metastatic non–small-cell l…
View article: Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer
Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung Cancer Open
Importance The combination of an antibody to programmed cell death-1 (PD-1) or to its ligand (PD-L1) with chemotherapy is the standard first-line treatment for metastatic non–small cell lung cancer (NSCLC). Bevacizumab is expected to enhan…
View article: Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non–Small Cell Lung Cancer
Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non–Small Cell Lung Cancer Open
Importance Biomarker testing for driver mutations is essential for selecting appropriate non–small cell lung cancer (NSCLC) treatment but is insufficient. Objective To investigate the status of biomarker testing and drug therapy for NSCLC …
View article: The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study
The combination of soluble forms of PD-1 and PD-L1 as a predictive marker of PD-1 blockade in patients with advanced cancers: a multicenter retrospective study Open
Introduction The clinical relevance of soluble forms of programmed cell death-1 (sPD-1) and programmed cell death-ligand 1 (sPD-L1) remains unclear. We here investigated the relation between the efficacy of PD-1 blockade and pretreatment p…
View article: Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer Open
View article: Liquid biopsy detects genomic drivers in <scp>NSCLC</scp> without <i>EGFR</i> mutations by single‐plex testing: <scp>WJOG13620L</scp>
Liquid biopsy detects genomic drivers in <span>NSCLC</span> without <i>EGFR</i> mutations by single‐plex testing: <span>WJOG13620L</span> Open
Background Actionable tumor genomic alterations, primarily EGFR mutations, occur in nearly 70% of Japanese advanced nonsquamous non‐small cell lung cancer (NSCLC) patients. Standard assessment of tumor tissue includes rapid testing for EGF…
View article: P2.06-06 Study Design to Assess Anti-TIGIT Mab Combination with Dostarlimab vs Pembrolizumab or Dostarlimab Monotherapy in NSCLC
P2.06-06 Study Design to Assess Anti-TIGIT Mab Combination with Dostarlimab vs Pembrolizumab or Dostarlimab Monotherapy in NSCLC Open
View article: MA05.10 Patient-Initiated a Phase II study (WJOG12819L) to Assess the Efficacy of Osimertinib in Patients with EGFR Mutated T790M-Negative NSCLC
MA05.10 Patient-Initiated a Phase II study (WJOG12819L) to Assess the Efficacy of Osimertinib in Patients with EGFR Mutated T790M-Negative NSCLC Open
View article: <i>NOTCH1</i> and <i>CREBBP</i> co‐mutations negatively affect the benefit of adjuvant therapy in completely resected <i>EGFR</i> ‐mutated <scp>NSCLC</scp> : translational research of phase <scp>III IMPACT</scp> study
<i>NOTCH1</i> and <i>CREBBP</i> co‐mutations negatively affect the benefit of adjuvant therapy in completely resected <i>EGFR</i> ‐mutated <span>NSCLC</span> : translational research of phase <span>III IMPACT</span> study Open
The phase III IMPACT study (UMIN000044738) compared adjuvant gefitinib with cisplatin plus vinorelbine (cis/vin) in completely resected epidermal growth factor receptor ( EGFR )‐mutated non‐small cell lung cancer (NSCLC). Although the prim…